Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.

Molecular Diagnosis & Therapy
Anthony Scimè, Michael A Rudnicki

Abstract

Duchenne muscular dystrophy (DMD) is a lethal heritable childhood myodegenerative condition caused by a mutation within the gene encoding the dystrophin protein within the X chromosome. While, historically, patients with this condition rarely lived into their thirties, they are now living substantially longer as a result of new treatments based on multi-disciplinary care. Despite these advances, the prognosis for DMD patients is limited, and a progressive reduction in quality of life and early death in adulthood cannot be prevented using currently available treatment regimens. The best hopes for a cure lies with cellular and gene therapy approaches that target the underlying genetic defect. In the past several years, viral and nonviral gene therapy methodologies based on adeno-associated viruses, naked plasmid delivery, antisense oligonucleotides, and oligonucleotide-mediated gene editing have advanced to a high degree of sophistication, to the extent that research has moved from the laboratory setting to the clinic. Notwithstanding these accomplishments, shortcomings with each therapy remain, so more work is required to devise an appropriate therapeutic strategy for the management and eventual cure of this debilitating disease.

References

Mar 23, 1990·Science·J A WolffP L Felgner
Mar 1, 1990·International Journal of Cardiology·G NigroR J Bain
Jun 15, 1989·The New England Journal of Medicine·J R MendellJ Florence
Jun 11, 1998·Journal of Pharmaceutical Sciences·D J WellsK E Wells
Sep 22, 1998·Nature Biotechnology·H Aihara, J Miyazaki
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·L M MirD Scherman
Aug 17, 1999·The Journal of Clinical Investigation·E R Barton-DavisH L Sweeney
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·T A RandoL Z Zhou
Feb 7, 2002·JAMA : the Journal of the American Medical Association·Anju NohriaLynne Warner Stevenson
Feb 28, 2002·Human Gene Therapy·Carmela MennuniNicola La Monica
Mar 5, 2002·Nature Medicine·Scott Q HarperJeffrey S Chamberlain
Jun 14, 2002·Neuromuscular Disorders : NMD·Alan E H Emery
Aug 15, 2002·BMC Molecular Biology·Pierre LefesvreDirk van Bekkum
Sep 11, 2002·Neuromuscular Disorders : NMD·Annemieke Aartsma-RusJudith C T van Deutekom
Nov 7, 2002·Developmental Medicine and Child Neurology·Denise G M McDonaldM G Pike
Nov 20, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gawiyou DanialouBasil J Petrof
Jan 28, 2003·Muscle & Nerve·Tatsufumi MurakamiYoshihide Sunada
Apr 2, 2003·Human Molecular Genetics·Annemieke Aartsma-RusJudith C T van Deutekom
Apr 30, 2003·Human Molecular Genetics·Carmen BertoniThomas A Rando
Dec 19, 2003·American Journal of Human Genetics·Annemieke Aartsma-RusJudith C T van Deutekom
Feb 24, 2004·The Journal of Gene Medicine·Véronique BlouinAnna Salvetti
May 28, 2004·Journal of Virology·Michael SchmidtJohn A Chiorini
Jul 27, 2004·Nature Medicine·Paul GregorevicJeffrey S Chamberlain
Aug 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·James E HagstromJon A Wolff
Aug 11, 2004·American Journal of Respiratory and Critical Care Medicine·Jonathan D FinderUNKNOWN American Thoracic Society

❮ Previous
Next ❯

Citations

Jul 1, 1990·Journal of the Neurological Sciences·H A John, I F Purdom
Aug 1, 2009·The Journal of Biological Chemistry·Denny L CottleChristina A Mitchell
Mar 19, 2009·ILAR Journal·Zejing WangRainer Storb
Mar 4, 2017·Circulation Research·Thomas Doetschman, Teodora Georgieva
Sep 10, 2013·Molecular Neurobiology·Pedro CisternasNibaldo C Inestrosa
Sep 17, 2009·Current Opinion in Neurology
Dec 23, 2009·Pediatrics·Anne Marie Catharina PlassMartina Cornelia Cornel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Related Papers

Current Opinion in Molecular Therapeutics
Michael Roberts, George Dickson
Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology
Carmen Bertoni
Experimental Physiology
Rebecca J FaircloughKay E Davies
© 2022 Meta ULC. All rights reserved